Hayden E. Klein

The treatment combined adoptive T-cell therapy with a personalized cancer vaccine and was found to be safe in a small cohort of 17 patients.

This approval marks the fourth endorsement by the FDA for empagliflozin, all of which have been linked to the EMPOWER program.

While B-type natriuretic peptide (BNP) levels remain high in patients with end-stage heart failure with cardiogenic shock, these levels lose their prognostic value in patients using ventricular assist devices (VADs).

A tailored electronic health record (EHR) alert system did not significantly increase the prescription of guideline-directed medical therapies (GDMT) at hospital discharge for patients with acute heart failure (AHF).

If clinicians empower individuals by giving them the appropriate tools and education to promote brain health, it can make a big difference, said Alvaro Pascual-Leone, MD, PhD.

The UPMC Health Plan Neighborhood Center, which first opened its doors in December 2022, offers a wide array of services to support plan members and others living in the community.

Patients now have higher expectations of us health care professionals, and we have to meet those expectations, said Donna Fitzsimons, PhD, FESC, professor of nursing at the School of Nursing and Midwifery, Queen's University Belfast.

Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute, explains how findings from the HEART-FID trial add to the value of ferric carboxymaltose injection.

Trials such as HEART-FID and AFFIRM-AHF have demonstrated positive treatment results for injectable ferric carboxymaltose in patients with heart failure and iron deficiency.

Secondary effects not only improved past 16 weeks, but showed a sustained improvement at week 56 of mavacamten, said Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.

Transcatheter aortic valve replacement (TAVR) demonstrated better short-term outcomes, while surgical aortic valve replacement (SAVR) had better long-term outcomes.

Despite not reaching statistical significance, findings from DICTATE-AHF show early dapagliflozin improved decongestion and led to earlier hospital discharge for patients with acute decompensated heart failure, explained Zachary Cox, PharmD, professor at Lipscomb University College of Pharmacy.

Results from ATLANTE/ENGOT-ov29 show that atezolizumab did not significantly improve progression-free survival (PFS) compared with placebo plus bevacizumab for patients with platinum-sensitive ovarian cancer.

Over the past 20 years, the age-adjusted mortality rate for obesity-related cardiovascular mortality increased by 415% for American Indian or Alaska Native individuals.

New research suggests an association between gestational diabetes history and mortality over 30 years, regardless of whether it manifests into type 2 diabetes.

New research suggests conventional fractionated and hypofractionated proton postmastectomy radiotherapy (PMRT) yield similar tolerability and complication rates for patients following mastectomy.

Across 65 cardiovascular guidelines with nearly 7500 specific recommendations published 2012-2022, only 170 recommendations directly incorporated shared decision-making.

Out of several factors, surgical complications were the only factor independently associated with emergency department (ED) readmission among patients who underwent surgery for ovarian carcinoma.

A patient-centered approach on top of a multifactorial approach will help patients adhere to lifestyle modifications, said Nikolaus Marx, MD, professor of medicine/cardiology and head of the Department of Internal Medicine, University Hospital Aachen, Germany.

After 16 weeks on placebo, patients in the control group were invited to start mavacamten alongside the treatment group, explained Milind Desai, MD, MBA, director of the Hypertrophic Cardiomyopathy Center and vice chair of education at the Heart, Vascular & Thoracic Institute, Cleveland Clinic.

There seems to be an institutional ignorance toward social determinants of health and actually making changes to improve outcomes for patients of color, said Shrilla Banerjee, MD, FRCP, consultant cardiologist, Surrey and Sussex Healthcare NHS Trust.

The EMPEROR trial showed that within 30 days of stopping empagliflozin, patients had a 70% higher risk of heart failure events, explained Milton Packer, MD, Baylor University Medical Center.

Nikolaus Marx, MD, professor of medicine/cardiology and head of the Department of Internal Medicine, University Hospital Aachen, Germany, explains the new guidelines on screening for patients with type 2 diabetes and comorbid cardiovascular disease (CVD).

When determining the success of cardiology therapies, trials should focus more on softer end points like quality of life and psychological well-being, said Donna Fitzsimons, PhD, FESC, professor of nursing at the School of Nursing and Midwifery, Queen's University Belfast.

There is a lot of drug switching that's happening, whether it's for medical or nonmedical reasons, said Steven Deitelzweig, MD, system chairman of hospital medicine at Ochsner Clinical School, professor of medicine at the University of Queensland.

With nearly a third of patients post-myocardial infarction (MI) developing heart failure, prevention is very important, said Javed Butler, MD, MPH, MBA, professor of medicine at University of Mississippi, president of the Baylor Scott & White Research Institute.

Attendees should look out for results from the STEP HFpEF program and HEART-FID trial at the European Society of Cardiology (ESC) Congress 2023, said Stephen Greene, MD, Duke University Medical Center and the Duke Clinical Research Institute.

Crystal Denlinger, MD, FACP, incoming CEO of the National Comprehensive Cancer Network (NCCN), talks about the organization’s challenges and solutions to keeping up with the ever-changing oncology landscape and improving patient access to guideline-recommended treatments.

Ahead of the European Society of Cardiology (ESC) Congress 2023, John McMurray, MD, FRCP, FESC, professor of medical cardiology at the University of Glasgow, previews some themes and important topics that will be discussed at the meeting.

The decrease in e-cigarette use between 2014 and 2019 may be linked to improved education on the harms of the devices, while the increase in 2019 could be attributed to worsened psychological burden during the COVID-19 pandemic.